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Introduction: Mitochondrial dysfunction is associated with increased mortality in septic shock. Coenzyme Q10
(CoQ10) is a key cofactor in the mitochondrial respiratory chain, but whether CoQ10 is depleted in septic shock
remains unknown. Moreover, statin therapy may decrease CoQ10 levels, but whether this occurs acutely remains
unknown. We measured CoQ10 levels in septic shock patients enrolled in a randomized trial of simvastatin versus
placebo.
Methods: We conducted a post hoc analysis of a prospective, randomized trial of simvastatin versus placebo in
patients with septic shock (ClinicalTrials.gov ID: NCT00676897). Adult patients with suspected or confirmed infection
and the need for vasopressor support were included in the initial trial. For the current analysis, blood specimens
were analyzed for plasma CoQ10 and low-density lipoprotein (LDL) levels. The relationship between CoQ10 levels
and inflammatory and vascular endothelial biomarkers was assessed using either the Pearson or Spearman
correlation coefficient.
Results: We analyzed 28 samples from 14 patients. CoQ10 levels were low, with a median of 0.49 (interquartile
range 0.26 to 0.62) compared to levels in healthy control patients (CoQ10 = 0.95 μmol/L ± 0.29; P < 0.0001). Statin
therapy had no effect on plasma CoQ10 levels over time (P = 0.13). There was a statistically significant relationship
between plasma CoQ10 levels and levels of vascular cell adhesion molecule (VCAM) (r
2 = 0.2; P = 0.008), TNF-a (r
2
= 0.28; P = 0.004), IL-8 (r
2 = 0.21; P = 0.015), IL-10 (r
2 = 0.18; P = 0.025), E-selectin (r
2 = 0.17; P = -0.03), IL-1ra (r
2 =
0.21; P = 0.014), IL-6 (r
2 = 0.17; P = 0.029) and IL-2 (r
2 = 0.23; P = 0.009). After adjusting for LDL levels, there was a
statistically significant inverse relationship between plasma CoQ10 levels and levels of VCAM (r
2 = 0.24; P = 0.01)
(Figure 3) and IL-10 (r
2 = 0.24; P = 0.02).
Conclusions: CoQ10 levels are significantly lower in septic shock patients than in healthy controls. CoQ10 is
negatively associated with vascular endothelial markers and inflammatory molecules, though this association
diminishes after adjusting for LDL levels.
Introduction
Severe sepsis and septic shock are major causes of mor-
bidity and mortality. The annual incidence of deaths
due to severe sepsis and septic shock is estimated to be
over 215,000 in the United States [1]. Organ dysfunction
related to sepsis is associated with significant alterations
in metabolic pathways and cellular function [2].
Although the exact mechanism by which sepsis leads to
organ dysfunction remains unclear, hypoxia and several
mediators in the systemic inflammatory response have
been shown to directly impair mitochondrial function
and may lead to increased morbidity and mortality in
patients with septic shock [3-5].
Coenzyme Q (CoQ10), or ubiquinone, is located
within the inner mitochondrial membrane and acts as
an electron transport mediator from complex I or
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CoQ10 may be obtained from dietary sources (including
food and oral supplementation), it is primarily synthe-
sized endogenously in the endoplasmic reticulum from
tyrosine and mevalonate and vitamins B2,B 9,B 12 and C
and is transported in the plasma by low-density lipopro-
tein (LDL) [6]. Low CoQ10 levels may result from
impairment in CoQ10 synthesis, decreased dietary
intake or increased requirement (such as during condi-
tions that increase oxidative stress), or from any combi-
nation of these factors. Previous investigations have
demonstrated that prolonged statin use may decrease
CoQ10 levels in patients with cardiovascular disease;
however, a causal effect of stain therapy on decreased
CoQ10 levels remains a topic of debate [7,8]. In addition
to the potential negative effect that statins may have on
CoQ10 levels, the increased metabolic demand resulting
from sepsis may also deplete CoQ10 levels.
Statins may hold therapeutic value for the prevention
and/or treatment of patients with sepsis. Previous investi-
gations have demonstrated important immunomodula-
tory activity of statins on the inflammatory response and
direct alterations of leukocyt e - e n d o t h e l i a lc e l li n t e r a c -
tions [9-11]. Furthermore, statin therapy has been asso-
ciated with decreased morbidity and mortality in patients
with sepsis [12]. However, statins may also decrease
levels of CoQ10, an essential component of the respira-
tory chain, leading to mitochondrial dysfunction [13].
The statin, CoQ10 and sepsis triangulation was
recently reviewed, and the lack of human data to sup-
port theoretical assumptions and hypotheses was noted.
Specifically, Brealey et al. [14] stated that low levels of
antioxidants cause mitochondrial dysfunction in human
sepsis, but there are currently no data to account for
the levels of the mitochondrial component CoQ10.
Herein we report on the levels of plasma CoQ10 in
patients with septic shock and the relationship between
CoQ10 and the inflammatory cascade. The primary goal
of this investigation was to determine whether patients
with septic shock have decreased plasma CoQ10 com-
pared to healthy controls. Our secondary aims were to
determine whether CoQ10 levels are associated with the
sepsis-induced inflammatory response and vascular
endothelial activation and to determine whether acute
statin therapy reduces CoQ10 levels [15-19]. We mea-
sured CoQ10 levels and inflammatory and vascular
endothelial biomarkers in plasma that had been col-
lected in a prospective, randomized trial of statins versus
placebo for patients with septic shock.
Materials and methods
Study design
We conducted a post hoc analysis of a prospective, rando-
mized trial of septic shock patients admitted to an urban
university teaching hospital (ClinicalTrials.gov ID:
NCT00676897). The initial trial was a prospective, rando-
mized, double-blind, placebo-controlled, single-center
trial of the effect of statin therapy for patients with septic
shock. Patients enrolled in the trial were given either 40
mg of simvastatin or placebo once daily for a maximum
of seven days or until hospital discharge, whichever came
first. The primary outcome for the initial trial was the
time until shock reversal with a secondary outcome of
attenuation of the inflammatory cascade following inter-
vention. The current post hoc analysis was performed
using clinical and inflammatory biomarker data collected
from the patients who were included in the initial trial.
The study was approved by the Institutional Review
Board at Beth Israel Deaconess Medical Center.
Study setting and population
All patients who presented to our urban university
teaching hospital with suspected or confirmed infection
were considered for enrollment. Patients were screened
by trained research assistants using the hospital’s elec-
tronic medical record system in the emergency depart-
ment and ICUs. Inclusion criteria for the initial trial
consisted of adult patients (age > 18 years) with two or
more of the four systemic inflammatory response syn-
drome criteria, suspected or confirmed infection (pneu-
monia, sepsis, pyelonephritis, and so on) and evidence
of shock (defined as the use of vasopressor medication
for a minimum of one hour). Exclusion criteria con-
sisted of statin or digoxin use upon presentation, alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels more than three times the upper limit of
normal or creatine phosphokinase level more than four
times the upper limit of normal. Patients were also
excluded if they did not require vasopressor support.
Healthy controls were enrolled if they met the inclusion
criteria of age > 18 years and no acute medical or surgi-
cal problems that would require hospital admission.
Controls were excluded if they had any significant
comorbid disease. Written informed consent was
obtained from the patients or their designated surro-
gates prior to any research intervention.
Interventions
All patients received standard medical therapy for the
treatment of the underlying infection as determined by
the clinical team. The initial randomized trial included
provision of either simvastatin 40 mg or placebo once
daily for a maximum of seven days or until hospital dis-
charge, whichever occurred first. Patients included in
the post hoc analysis were assessed for clinical and bio-
marker data, including levels of CoQ10 and plasma LDL
as well as vascular endothelial and inflammatory
markers.
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Pertinent patient demographics, including age, gender,
race, medical history and suspected source of infection
were recorded at baseline. Vital signs and laboratory
data, including complete blood count, electrolytes and
lactate, were recorded at the time of enrollment and at
serial time intervals.
Blood was collected at serial time intervals (0, 24, 48,
72 and 168 hours) into evacuated tubes containing ethy-
lenediaminetetraacetic acid from an existing venous or
arterial catheter. The blood was immediately centrifuged
at 2,800 × g at 4°C for 10 minutes, and 0.5 mL of
plasma were transferred into cryogenic vials and stored
at -80°C immediately after centrifugation. Samples from
patients who had blood collected at both 0 and 72
hours were used in the current biomarker analysis.
Primary data analysis
Cytokine and soluble cardiovascular biomarker
measurement
Plasma from patients and controls at 0 and 72 hours
was collected and stored at -80°C until thawed to assay
for cytokines and soluble cardiovascular biomarkers.
Analytes were measured by multiplex analysis (Bio-Plex
Laboratories, Hercules, CA, USA) using 96-well multi-
plex kits (Millipore, Billerica, MA, USA). Analytes mea-
sured were IL-1ra, IL-2, IL-6, IL-8, IL-10, TNF-a,
vascular endothelial growth factor (VEGF), soluble E-
selectin, soluble vascular cell adhesion molecule
(VCAM) and soluble intercellular adhesion molecule
(ICAM). For vascular biomarkers (E-selectin, VCAM
and ICAM), plasma samples were measured at either
1:50 or 1:100 dilution factor. For cytokines and VEGF
plasma, samples were measured undiluted. All samples
were measured in duplicate (mean values from duplicate
results were used for analysis).
Plasma coenzyme Q10 measurement
Plasma CoQ10 levels were measured at the Laboratories
of Metabolic and Mitochondrial Diseases at Columbia
University, where analysis of CoQ10 is performed for
both commercial and research purposes. Concentrations
of CoQ10 were measured by using high-pressure liquid
chromatography (HPLC) with an electrochemical detec-
tion system. Briefly, 50 μL of thawed plasma were mixed
in an Eppendorf tube with 50 μL of ethanol solution
containing 25 ng of CoQ9 (used as internal standard).
After the addition of 900 μL of 1-propanol, the tube was
vortex-mixed for 2 minutes and then centrifuged at high
speed in the cold room for 10 minutes. An aliquot
(about 300 μL) of the supernatant was filtered through a
0.2-μm filter column and transferred into an HPLC
sample injection vial, and an aliquot of 50 μLo ft h e
extract was injected into an HPLC system equipped
with a C18 reversed-phase column and an ESA
Coulochem II electrochemical detector (ESA, Inc.,
Chelmsford, MA, USA). The established healthy control
CoQ10 concentration range in the literature is 1.04
μmol/L ± 0.33, though we measured a set of healthy
controls in this study to provide direct comparison and
validate our methods [20].
Statistical methods
Basic demographics and patient characteristics are
reported using descriptive statistics. Continuous data are
reported as medians with interquartile ranges (IQRs),
and categorical data are reported as frequency with per-
centages. As LDL is the primary transport molecule for
CoQ10, the ratio of CoQ10 to LDL (CoQ10:LDL) levels
was calculated, and these values were used for subse-
quent analyses. CoQ10 levels in the septic population
were compared to healthy controls using the Wilcoxon
rank-sum test. The relationship between CoQ10 and
inflammatory and vascular endothelial biomarkers was
assessed using either the Pearson or Spearman correla-
tion, depending on the normality of the data. Statistical
analysis was performed using SAS version 9.2 software
(SAS Institute, Cary, NC, USA), and P <0 . 0 5w a sc o n -
sidered significant for statistical testing of the data.
Power calculation
Miles et al. [20] previously reported healthy control
values for CoQ10 (1.04 μmol/L ± 0.33). Thus, assuming
a 30% lower value in septic shock patients with a similar
standard deviation, our study has 80% power to detect a
difference between groups (a = 0.05) with a sample size
of 28 septic patients and 16 controls.
Results
A total of 18 subjects were randomized in the initial
trial. Of these 18 patients, one patient died prior to the
72-hour follow-up examination and three had no fol-
low-up blood specimen available and were therefore
excluded from the current analysis. Of the 18 patients
in the original trial, 14 had CoQ10 levels measured at
both 0 and 72 hours, and these 28 samples were
included in our analysis (Figure 1). The baseline charac-
teristics of these 14 patients are provided in Table 1. In
addition, we measured CoQ10 levels in 16 healthy con-
trols. The median age of the septic shock patients was
55 years (IQR 47 to 62 years), and 64% of them were
females. The severity of illness was assessed using the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score, with a median score of 19 (IQR 17
to 21). There was no difference in severity of illness
between groups in the initial trial on the basis of
APACHE II scoring (placebo: 19 (IQR 18 to 20), statin:
17 (IQR 16 to 21)) or lactic acid (placebo: 2.0 mmol/L
(IQR 1.9 to 2.2), statin: 2.3 mmol/L (IQR 1.3 to 3.3)).
CoQ10 levels for the patients were low, with a median
of 0.49 μm o l / L( I Q R0 . 2 6t o0 . 6 2 ) .T h em e d i a nL D L
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the CoQ10:LDL ratio was 101 (IQR 82 to 150). CoQ10
levels in the patient group were statistically significantly
lower than in the 16 healthy controls (0.95 μmol/L ±
0.29; P < 0.0001). Of note, our control values of CoQ10
were similar to previously established healthy control
ranges, thus validating our methods (1.04 μmol/L ± 0.33
μmol/L) [20]. Randomization from the initial trial had
no effect on CoQ10 level (Figure 2). Specifically, there
was no significant difference in the change in mean
CoQ10 levels between randomization groups (P =0 . 1 3 ) ,
though there appears to have been a slight trend toward
decreases in the statin group. There was a statistically
significant relationship between CoQ10 level and
VCAM (r
2 =0 . 2 ;P = 0.008), TNF-a (r
2 = 0.28; P =
0.004), IL-8 (r
2 =0 . 2 1 ;P = 0.015), IL-10 (r
2 =0 . 1 8 ;P =
0.025), E-selectin (r
2 = 0.17; P = -0.03), IL-1ra (r
2 =
0.21; P = 0.014), IL-6 (r
2 =0 . 1 7 ;P = 0.029) and IL-2 (r
2
= 0.23; P = 0.009). After adjusting for LDL levels, there
were statistically significant inverse relationships
Figure 1 Schematic of our study design. A total of 28 samples were analyzed (14 patients with baseline and follow-up blood specimens were
included for analysis).
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2 = 0.24; P = 0.01) (Figure
3) and IL-10 (r
2 = 0.24; P = 0.02). Additional biomarkers
demonstrated no association with CoQ10 after adjust-
ment for plasma LDL (all P > 0.05).
Discussion
To the best of our knowledge, this is the first report on
the levels of CoQ10 in humans with septic shock. In
this post hoc analysis of a prospective, randomized trial,
we found that patients in septic shock have significantly
lower levels of plasma CoQ10 compared to a normal
healthy control population [20]. Furthermore, we found
a statistically significant inverse relationship between
plasma CoQ10 levels with inflammatory cytokines and
vascular endothelial biomarkers.
CoQ10 is an essential component of the electron
transport chain, acting as an electron transporter of
mitochondrial complexes I and II to complex III. Dis-
ruption of this mechanism can compromise the oxida-
tive capacity of the mitochondria and lead to a
decreased level of energy production. Mitochondria are
the primary organelles for cellular energy production,
and mitochondrial dysfunction can be detrimental in
critical illness. The presence of mitochondrial
Table 1 Baseline patient characteristics
a
Demographics Data (N = 14)
Age, years 55 (47 - 62)







Chronic obstructive pulmonary disease 2 (14)
Coronary artery disease 2 (14)
Congestive heart failure 3 (21)
Renal insufficiency or end-stage renal disease 4 (29)
Initial vital signs
Temperature (°F) 98.9 (97.0 - 100.0)
MAP (mmHg) 64 (54 - 83)
Heart rate (bpm) 99 (88 - 112)
Respiratory rate (breaths/minute) 20 (16 - 23)
Initial laboratory data
Sodium (mEq/L) 140 (137 - 140)
Potassium (mEq/L) 3.8 (3.1 - 4.2)
Bicarbonate (mEq/L) 19 (16 - 24)
Creatinine (mg/dL) 1.5 (0.9 - 3.5)
INR 1.2 (1.2 - 1.5)
AST (IU/L) 29 (7 - 35)
ALT (IU/L) 29 (19 - 45)
White blood cells (1 × 10
3/μL) 10.5 (6 - 16)
Hematocrit (%) 31 (29 - 34)
Platelets (1 × 10
3/μL) 196 (164 - 302)
Arterial blood gas
pH 7.36 (7.29 - 7.42)
PaCO2 (mmHg) 38 (30 - 51)
PaO2 (mmHg) 101 (75 - 113)
Lactate (mmol/L) 2.1 (1.4 - 2.4)
CoQ10 data
CoQ10 (μmol/L) 0.49 (0.26 - 0.62)
LDL (mg/dL) 42 (35 - 61)
CoQ10:LDL ratio 101 (82 - 150)
aALT: alanine aminotransferase, AST: aspartate aminotransferase, CoQ10:
plasma coenzyme Q10, INR: International Normalized Ratio, LDL: low-density
lipoprotein, MAP: mean arterial pressure, PaCO2, partial pressure of carbon
dioxide, PaO2: partial pressure of oxygen. Data are medians with interquartile
ranges unless otherwise indicated.
Figure 2 Comparison of ratios of coenzyme Q10 to low-density
lipoprotein (CoQ10:LDL) between randomization groups in the
parent trial. There was no significant difference in the change in
plasma CoQ10 between the statin and placebo groups (P = 0.13).
Bars are Standard Error of the Mean.
Figure 3 Association between CoQ10 and sVCAM1, soluble
vascular cell adhesion molecule levels (P = 0.04).
Donnino et al. Critical Care 2011, 15:R189
http://ccforum.com/content/15/4/R189
Page 5 of 8dysfunction in septic shock has been described pre-
viously, though the exact components and reasons for
this dysfunction are not completely known [3-5]. The
hypothesis that CoQ10 deficiency contributes to mito-
chondrial dysfunction remains plausible. Our findings
that plasma CoQ10 levels are abnormally low in a septic
shock cohort compared to healthy adults supports this
potential link.
Previous research studies have demonstrated that
inflammatory cytokines and vascular endothelial markers
are abnormally elevated in septic shock, indicating both
inflammation and activation of the vascular endothe-
lium. Within septic patients, elevation of these biomar-
kers has been associated with worse outcomes [15-18].
We found a statistically significant association between
CoQ10 levels and VCAM and IL-10; whether the rela-
tionship is causal remains unknown. However, CoQ10
treatment in other diseases, such as breast cancer, did
show that provision of the compound ultimately
resulted in a lowering of biomarkers, thus supporting a
causal relationship [21].
The finding of abnormally low CoQ10 levels is consis-
tent with the expected pathophysiology in septic shock.
Since LDL is the primary transport molecule for CoQ10
in plasma, we measured LDL levels and found that
these levels were low, which is in agreement with
reports in the literature on lipoprotein variations in sep-
sis and septic shock [22]. The decrease in the carrier
may lead to depletion of CoQ10. In addition, CoQ10 is
partially provided by diet, and patients with critical ill-
ness often have nutritional deficiencies for multiple rea-
sons. Furthermore, through a series of complex
biochemical reactions, CoQ10 is synthesized endogen-
ously from a number of components, including mevalo-
nate and tyrosine as well as vitamins B2,B 9,B 12 and C.
Patients in septic shock have deficiencies in micronutri-
ents, including B vitamins, and since CoQ10 in the body
is primarily derived from endogenous production, meta-
bolic dysfunction leading to decreased production and/
or increased utilization is more likely to account for
CoQ10 depletion identified in this study [23]. Regardless
of etiology, identifying low CoQ10 levels in patients
with septic shock is significant, as the compound is
essential to mitochondrial function and may play an
important role in the pathophysiology of mitochondrial
dysfunction in sepsis. In contrast to previous investiga-
tions of mitochondrial dysfunction, our finding that
CoQ10 is low in sepsis opens the potential for future
therapeutic interventions, as CoQ10 can be administered
exogenously.
In experimental models, pretreatment with CoQ10
before induction of sepsis restored hepatic ATP levels,
suppressed markers of lipid peroxidation and increased
survivability [2]. In a canine model of septic shock, Lelli
et al. [24] found that pretreatment with CoQ10 led to
improvements in cardiac output and mean arterial pres-
sure, though they did not find statistically significant dif-
ferences in several biomarkers, including TNF-a and IL-
6. However, they had a very small sample size (10 dogs,
5 in each group), and they indicated that IL-6, for
instance, increased by approximately 3,000% over the
baseline level (prior to injection with Escherichia coli)
compared to an approximately 500% increase in the
group that was infused with CoQ10 in addition to E.
coli, even though this did not reach statistical signifi-
cance with such a small sample size. A relationship
might have been found with a larger sample. In addi-
tion, there were multiple markers measured in our
study that were not measured by Lelli and colleagues
[24]. Thus, the improvements in cardiovascular function
that these investigators found may be linked to modifi-
cations of vascular or inflammatory biomarkers.
We detected no significant effect of statin therapy on
plasma CoQ10 levels in our population; however, our
sample size was too small to draw any definitive conclu-
sions, and we did note a trend toward decreases in the
statin group as compared to placebo. In 1993, Watts et
al. [25] reported that patients undergoing statin therapy
for hyperlipidemia had significantly reduced CoQ10
levels. However, their investigation was cross-sectional
in design and thus they could not determine a causal
association between statin use and decreased CoQ10
levels.
The current study has several limitations which must
be considered when interpreting the data. First, the sam-
p l es i z ei no u rs t u d yw a ss m a l l .T h ec o m p a r i s o no ft h e
total data set of 28 patients to 16 healthy controls is
likely robust enough to conclude that CoQ10 levels are
decreased in sepsis; however the effect of statins on
CoQ10 is less clear, particularly because of our small
sample size. Second, there were a number of patients in
septic shock who were not included in the data analysis,
as they did not meet all inclusion criteria for the initial
prospective, randomized trial. For example, we defined
“shock” as the requirement for vasopressors for a mini-
mum of one hour, and septic patients who were not
vasopressor-dependent were not considered for enroll-
ment in the initial trial. Therefore, larger prospective
observational trials measuring CoQ10 in this patient
population are required.
Conclusions
CoQ10 levels are abnormally low in patients with septic
shock compared to controls. The clinical significance of
this abnormality remains unknown but should be
explored, given the essential role that CoQ10 has in the
electron transport chain. Low levels of CoQ10 may be
associated with high levels of inflammatory cytokines
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for LDL (carrier of CoQ10) diminishes this association
and may explain this finding.
Key messages
￿ Plasma CoQ10 levels are low in human septic
shock.
￿ There may be an association between plasma
CoQ10 levels and the inflammatory cascade in
human septic shock.
￿ Statin therapy administered to patients in septic
shock had no effect on CoQ10 levels.
￿ Additional research should be conducted to inves-
tigate the potential of CoQ10 as a therapeutic agent
for patients in septic shock.
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